Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Swidnica – page 39

985 clinical trials in Swidnica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Swidnica at a glance
985
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

985 trials in Swidnica

Open in trial search

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Janssen Cilag International

Sjogren's syndrome

Not recruiting

Title: Study of Sibeprenlimab Treatment for Adults with Sjögren's Disease Using Subcutaneous Injections

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development And Commercialization Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lunsekimig (SAR443765) for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of AMG 193 tablets for patients with advanced non-small cell lung cancer (NSCLC) who have previously received treatment and have MTAP gene deletion

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Swidnica

What the registry says about research in the country

01 Inflammatory Conditions

Innovative research focusing on inflammatory disorders, including trials evaluating new treatments for psoriatic arthritis and rheumatoid arthritis. Studies aim to assess novel therapeutic approaches using biologics and targeted medications.

  • Psoriatic Arthritis Studies
  • Rheumatoid Arthritis Treatment
  • Inflammatory Disease Management

Advanced therapies being tested to improve patient outcomes and quality of life.

02 Gastrointestinal Research

Comprehensive studies investigating treatments for inflammatory bowel diseases, including trials for Crohn's Disease and ulcerative colitis. Research focuses on novel therapeutic agents and long-term disease management.

  • Crohn's Disease Therapies
  • Ulcerative Colitis Treatments
  • Long-term Disease Management

Multiple trials exploring innovative approaches to treating gastrointestinal conditions.

03 Metabolic and Pain Management

Studies addressing obesity, knee osteoarthritis, and chronic pain conditions. Research includes evaluation of new medications for weight management and innovative approaches to pain relief.

  • Weight Management Therapies
  • Osteoarthritis Treatment
  • Pain Management Solutions

Cutting-edge research combining multiple therapeutic approaches for complex conditions.

04 Specialty Conditions

Focused research on unique conditions including thyroid eye disease, chronic spontaneous urticaria, and rotator cuff tendinopathy. Studies aim to develop targeted treatments for these specific medical needs.

  • Endocrine Disorders
  • Autoimmune Conditions
  • Musculoskeletal Treatments

Specialized therapeutic approaches for distinct medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.